Nasdaq Moves to Delist Adial Pharmaceuticals Over Equity Shortfall
ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.2× avg).
Summary
Nasdaq has formally notified Adial Pharmaceuticals that it no longer meets the minimum stockholders' equity requirement, giving the company 45 days to submit a compliance plan. To regain compliance, the company plans to seek stockholder approval to convert preferred stock.
Key Events · Legal and Risk Events · ADIL
-
Nasdaq Delisting Notice Received
On August 18, 2026, Nasdaq notified Adial that it no longer satisfies the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1), based on the 10-Q for the period ended June 30, 2026.
-
45-Day Compliance Plan Deadline
Adial has until October 2, 2026, to submit a compliance plan to Nasdaq. If accepted, the company may receive up to 180 days from August 18, 2026, to regain compliance.
-
Preferred Stock Conversion as Remedy
The company intends to seek stockholder approval at the 2026 Annual Meeting to convert its outstanding Series A Non-Voting Convertible Preferred Stock, which it believes will restore compliance with the equity requirement.
-
Hearing Rights if Plan Rejected
If the compliance plan is not accepted or compliance is not regained, Adial can request a hearing before Nasdaq's Hearing Panel, which would stay any delisting action pending the hearing process.
Analysis · ADIL · Life Sciences
A formal delisting notice from Nasdaq landed on August 18, 2026, after Adial Pharmaceuticals' stockholders' equity slipped below the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. The company now has 45 days to submit a compliance plan and intends to seek stockholder approval to convert Series A preferred stock, a move it believes will restore compliance. While this formalizes the listing deficiency previously disclosed in the 10-Q and adds a concrete deadline and potential path to resolution, the risk of delisting remains significant.
At the time of this filing, ADIL was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.3M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.